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Abstract
Essential hypertension is a proinflammatory, proconstrictor disease coinciding with endothelial dysfunction and 
inward vessel remodeling. Using the skin circulation, our aim was to determine whether inducible NO synthase 
(iNOS) upregulation attenuates NO-dependent cutaneous vasodilation in hypertensive humans. We hypothesized 
that, with hypertension, localized iNOS inhibition would restore vasodilation in response to NO-dependent stimuli, 
and iNOS expression would be increased and phosphorylated vasodilator-stimulated phosphoprotein would be 
decreased. For, in vivo protocols, 4 intradermal microdialysis fibers were placed in 9 hypertensive and 10 
normotensive men and women (systolic blood pressure: 146±4 versus 113±2 mm Hg; P<0.001). Microdialysis 
fibers served as control, iNOS inhibited (1400 W), neuronal NO synthase inhibited (Nω-propyl-l-arginine), and 
nonselective NOS inhibited (NG-nitro-l-arginine methyl ester). Cutaneous vascular conductance was calculated 
(percentage of sodium nitroprusside) during standardized local heating (42°C) and acetylcholine dose-response 
protocols (0.01, 0.10, 1.00, 5.00, 10.00, 50.00, 100.00 mmol/L). The NO-dependent local heating response was 
attenuated at control (95±2% versus 76±2% cutaneous vascular conductance; P<0.05) and neuronal NO 
synthase–inhibited sites (94±4% versus 77±3% cutaneous vascular conductance; P<0.01) in hypertensives. iNOS 
inhibition augmented the NO-dependent local heating response (93±2% versus 89±10% cutaneous vascular 
conductance). Acetylcholine-induced vasodilation was attenuated in control sites at doses ≥0.1 mmol/L of 
acetylcholine in hypertensives and was restored with iNOS inhibition (0.1 mmol/L, P<0.05; 1, 5, and 10 mmol/L, 
P<0.001; 50 and 100 mmol/L, P<0.01). In vitro iNOS expression was increased (P=0.006) and phosphorylated 
vasodilator-stimulated phosphoprotein was decreased in skin from hypertensive humans (P=0.04). These data 
suggest that iNOS is upregulated in essential hypertensive humans and contributes to reduced NO-dependent 
cutaneous vasodilation.
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Abstract—Essential hypertension is a proinflammatory, proconstrictor disease coinciding with endothelial dysfunction and 
inward vessel remodeling. Using the skin circulation, our aim was to determine whether inducible NO synthase (iNOS) 
upregulation attenuates NO-dependent cutaneous vasodilation in hypertensive humans. We hypothesized that, with 
hypertension, localized iNOS inhibition would restore vasodilation in response to NO-dependent stimuli, and iNOS 
expression would be increased and phosphorylated vasodilator-stimulated phosphoprotein would be decreased. For, in 
vivo protocols, 4 intradermal microdialysis fibers were placed in 9 hypertensive and 10 normotensive men and women 
(systolic blood pressure: 1464 versus 1132 mm Hg; P0.001). Microdialysis fibers served as control, iNOS 
inhibited (1400 W), neuronal NO synthase inhibited (N-propyl-L-arginine), and nonselective NOS inhibited (NG-nitro-
L-arginine methyl ester). Cutaneous vascular conductance was calculated (percentage of sodium nitroprusside) during
standardized local heating (42°C) and acetylcholine dose-response protocols (0.01, 0.10, 1.00, 5.00, 10.00, 50.00,
100.00 mmol/L). The NO-dependent local heating response was attenuated at control (952% versus 762% cutaneous
vascular conductance; P0.05) and neuronal NO synthase–inhibited sites (944% versus 773% cutaneous vascular
conductance; P0.01) in hypertensives. iNOS inhibition augmented the NO-dependent local heating response (932%
versus 8910% cutaneous vascular conductance). Acetylcholine-induced vasodilation was attenuated in control sites at
doses 0.1 mmol/L of acetylcholine in hypertensives and was restored with iNOS inhibition (0.1 mmol/L, P0.05; 1,
5, and 10 mmol/L, P0.001; 50 and 100 mmol/L, P0.01). In vitro iNOS expression was increased (P0.006) and
phosphorylated vasodilator-stimulated phosphoprotein was decreased in skin from hypertensive humans (P0.04).
These data suggest that iNOS is upregulated in essential hypertensive humans and contributes to reduced NO-dependent
cutaneous vasodilation.
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Hypertension-related vascular dysfunction involves acomplex interaction of inflammation, endothelial dys-
function, including a loss of endothelial NO, and an upregu-
lation of proconstrictor pathways.1–3 The pathogenesis of
hypertension-associated microvascular dysfunction occurs si-
multaneously in multiple vascular beds.4,5 The cutaneous
circulation is an accessible, representative vascular bed for
the assessment of mechanisms underlying microvascular
dysfunction with essential hypertension.5–10 Deficits in mi-
crovascular reactivity, including a loss of NO signaling, and
inward vessel remodeling are clearly evident in essential
hypertensive human skin and parallel vascular changes that
occur in the renal circulation with essential hypertension.5
However, the precise mechanisms leading to this dysfunction
are unclear.
One putative mechanism underlying hypertension-related
microvascular dysfunction is through inducible NO synthase
(NOS; iNOS).11,12 iNOS generates high concentrations of
NO, which is easily converted to peroxynitrite and superoxide
in the pro-oxidant environment characteristic in essential
hypertension. In addition, iNOS also upregulates arginase
activity, which limits NO production through endothelial
NOS (eNOS)13 by preferentially using the common substrate
L-arginine and is capable of inducing NOS uncoupling.14 We
have demonstrated that acute localized arginase inhibition
augments NO-dependent vasodilation in essential hyperten-
sive human skin15,16; however, alterations in NO production
and the role of iNOS are unknown. Therefore, the purpose of
the present study was to examine the contributions of consti-
tutively expressed and iNOS isoforms in the cutaneous
vasculature of essential hypertensive humans using both
physiological and pharmacological stimuli to induce endothe-
lium-dependent vasodilation.17 We hypothesize that in vivo
attenuated vascular reactivity in essential hypertensive hu-
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mans results from compromised eNOS-derived NO-
dependent dilation and that acute iNOS inhibition would
augment NO-dependent vasodilation in hypertensive humans
induced by local heating of the skin or perfusion of the
endothelium-dependent agonist acetylcholine (Ach). We fur-
ther hypothesized that in vitro iNOS expression would be
increased and the downstream indicator of NO vasodilatory
function in vascular smooth muscle, vasodilatory-stimulated
phosphoprotein (VASP), would be decreased in skin samples
obtained from humans with essential hypertension.
Methods
Subjects
Experimental protocols were approved by the institutional review
board at Pennsylvania State University and conformed to the
guidelines set forth by the Declaration of Helsinki. Verbal and
written consent were voluntarily obtained from all of the subjects
before participation. Subject characteristics are presented in Table 1.
Blood pressure status was determined in accordance with the
guidelines set forth by the American Heart Association18 and further
explored using 24-hour ambulatory blood pressure monitoring.
Subjects underwent a complete medical screening and were other-
wise healthy with the exclusion of stage 1 hypertension and were not
taking any medications, including antihypertensives. Seven of the 8
essential hypertensive subjects were naive to antihypertensive phar-
macotherapy, and 1 subject had previously been taking antihyper-
tensive drugs but had not taken the drug for more than a year. All of
the premenopausal women (N2) were studied on days 2 to 7
of their menstrual cycle, and postmenopausal women (N8) re-
ported that it had been 1 year since the cessation of their last
menses. No perimenopausal women were studied.
In Vivo Vasoreactive Studies
Protocols were performed in a thermoneutral laboratory with the
subject semisupine and the experimental arm at heart level. Four
intradermal microdialysis fibers (MD 2000, Bioanalytical Systems)
were inserted into the forearm skin, as described previously.19
Microdialysis sites were perfused with ringers to serve as control,
0.1 mmol/L of 1400 W {N-[3-(aminomethyl)benzyl] acetamidine,
AG Scientific} to inhibit iNOS, 5 mmol/L of N-propyl-L-arginine
(Tocris) to inhibit neuronal NOS (nNOS), and 20 mmol/L of
NG-nitro-L-arginine methyl ester (L-NAME; Tocris) to nonselec-
tively inhibit all of the NOS isoforms (FDA IND 105 572) at a rate
of 2 L/min (Bioanalytical Systems Beehive and Baby Bee micro-
infusion pumps, West Lafayette, IN). All of the drugs were mixed
just before usage, dissolved in lactated Ringer solution, and sterilized
(Acrodisc, Pall, Ann Arbor, MI). The efficacies of the isoform-
specific antagonism and concentrations of the pharmacological
agents used in this study have been demonstrated in other microdi-
alysis studies (1400 W inhibition constant  7 nmol/L; N-propyl-
L-arginine inhibition constant  57 nmol/L).13,20–25
Local Heating Protocol
After subsidence of initial insertion trauma (60–120 minutes), local
skin temperature was clamped at 33°C and laser Doppler probes
attached over each site. After baseline measurements, a standardized
local skin warming protocol was performed to induce NO-dependent
vasodilation.26 This protocol induced cutaneous vasodilation that is
predominantly (70%) mediated by the production of NO from
eNOS.17,27,28 No subjects reported pain or a burning sensation during
skin heating. After skin blood flow reached an established plateau
(30–40 minutes), 20 mmol/L of L-NAME was perfused to quantify
NO-dependent vasodilation in all of the sites. A representative
tracing illustrating the phases of the local heating response from a
normotensive and a hypertensive subjects’ control sites are illus-
trated in Figure 1. This figure shows the phases of the local heating
response including the initial peak and nadir, which are primarily
mediated by sensory nerve mechanisms with a small NO contribu-
tion, followed by the predominantly NO-dependent plateau as
illustrated by the infusion of L-NAME to quantify the functional
production of NO.26 After a new post–L-NAME stabilization in skin
blood flow, local temperature was increased to 43°C and 28 mmol/L
of sodium nitroprusside was perfused to induce maximal cutaneous
vasodilation (CVCmax).21,29 In our previous work and in pilot work
this combination of heat and high concentration of sodium nitroprus-
side has been shown to induce maximal vasodilation.21
Ach Dose-Response Protocol
Subsidence of insertion trauma and baseline measurement followed
the same procedure as for the local heating. Protocols were per-
formed on the same arm and separated by 1 week to allow the skin
to fully heal between trials. After baseline measurement, local skin
temperature remained clamped at 33°C during perfusion of 7
ascending concentrations of Ach for 5 minutes each: 0.01, 0.10, 1.00,
5.00, 10.00, 50.00, and 100.00 mmol/L of Ach. This amount of time
allowed for a plateau in skin blood flow at each concentration of
Ach. Each Ach concentration was mixed with the appropriate
isoform-specific NOS inhibitor and perfused at 2 L/min. After
completion of the Ach dose response, local skin temperature was
increased to 43°C and 28 mmol/L of sodium nitroprusside was
perfused through all of the sites at a rate of 4 L/min to induce
CVCmax.21,29
In Vitro Skin Sample Analysis
Ventral forearm skin samples were obtained on a separate day from
the in vivo functional assessment of vasoreactivity and on the
opposite arm. Using sterile technique, two 3-mm–diameter skin
samples were obtained after anesthetization using 2% lidocaine
without epinephrine. Samples were immediately frozen in liquid
nitrogen and stored at 80°C until analysis.
Western Blot Analysis
After centrifugation of skin homogenates twice at 15 000g at 4°C for
20 minutes, protein concentration was determined using a Bio-Rad
DC protein assay. For Western blot analysis, 25-g proteins were
fractionated by SDS/PAGE and electrotransferred to a nitrocellulose
membrane (Hybond-ECL, Amersham Life Sciences). The mem-
branes were blocked for 1 hour at room temperature (5% nonfat dry
milk, in Tris-buffered saline containing 0.1% Tween 20) and
incubated with a primary antibody to eNOS (Santa Cruz Biotech-
nology; 1:1000); nNOS (BD Bioscience, 1:1000); iNOS (BD Bio-
science, 1:1000); and phosphorylated vasodilator-stimulated phos-
phoprotein (1:1000; Cell Signaling). Bound antibody was detected
with horseradish-peroxidated–conjugated IgG secondary antibody
(1:1000; Santa Cruz Biotechnology) and visualized using enhanced
chemiluminescence. Next, the phosphorylated vasodilator-
stimulated phosphoprotein (pVASP) blot was stripped using Restore
Plus Western Blot Stripping Buffer (Thermo Scientific) and reprobed
with VASP antibody (Cell Signaling). GAPDH was used as loading
Table 1. Participant Characteristics
Characteristic Normotensive Hypertensive
Subjects, men, women 3, 7 7, 2
Age, y 521 532
Body mass index 251 271
Systolic blood pressure, mm Hg 1133 1464*
Diastolic blood pressure, mm Hg 732 932*
Mean arterial pressure, mm Hg 862 1113*
Glucose, mg  dL1 903 943
High-density lipoprotein, mg  dL1 625 574
Low-density lipoprotein, mg  dL1 1104 1067
*P0.01 difference from the normotensive age-match control group.
control. Densitometry analyses were performed using Image J
software (National Institutes of Health).
Data and Statistical Analyses
Skin blood flow data were digitalized at 40 Hz, recorded, and stored
for offline analysis using Windaq software and Dataq data acquisi-
tion system (Windaq; Dataq Instruments, Akron, OH). Data were
normalized to a percentage of CVCmax. CVC data were averaged
over a stable 5 minutes of baseline, local heating plateau, post–L-
NAME plateau, and maximal vasodilation. The initial peak and nadir
CVC were visually identified as the highest and lowest values and
averaged over 10 seconds. The vasodilation attributed to NO was
calculated from the difference between the plateau and the post–L-
NAME plateau (Figure 1). Absolute CVCmax in each site was
calculated as the average of a stable plateau in laser-Doppler flux
during 28 mmol/L of sodium nitroprusside infusion and local heating
to 43°C divided by mean arterial pressure (Table 2). Because the late
plateau phase of the local heating response is primarily dependent on
NOS function, whereas the early phase has contributions from both
sensory nerves and NOS, analysis and further discussion focus on the
later phase of the cutaneous vasodilatory response.
Student unpaired t tests were used to compare physical char-
acteristics between subject groups and to examine potential
differences in the densitometry analysis of the Western blots.
Absolute CVCmax data were analyzed using a 2-way repeated-
measures ANOVA (group*pharmacological site, SPSS 19). %CVCmax
were analyzed using 3-way, mixed model, repeated-measures ANOVA
(group*pharmacological site*local heating phase or Ach dose; proc mix
SAS 9.2). Specific planned comparisons were performed when appro-
priate to determine where differences between groups and pharmaco-
logical sites occurred with appropriate Bonferroni correction. Signifi-
cance was set at 0.05. Values are presented as meanSEM.
Results
The physical characteristics of the subjects are presented in
Table 1. Subjects were matched for age, body mass index,
total cholesterol, and high- and low-density lipoproteins.
Hypertensive subjects showed a significantly higher resting
systolic, diastolic, and mean arterial blood pressure compared
with normotensive controls (P0.001).
Figure 1 illustrates representative skin blood flow tracings
during local heating for a normotensive and essential hyper-
tensive subject. The characteristic phases of the local heating
response are labeled.
Figure 2 illustrates the %CVCmax at the NO-dependent
plateau and after NOS inhibition with the nonspecific NOS
inhibitor L-NAME during local skin warming at different
pharmacological sites in normotensive controls and essential
hypertensive subjects. The difference between the plateau and
the post–L-NAME plateau is a quantification of within-site
NO-dependent vasodilation during local heating and is la-
beled numerically on the graph. The NO-dependent plateau
was attenuated in the hypertensive (HT) group at control (HT:
792% versus the normotensive group [NT]: 952% CVCmax;
P0.024) and nNOS inhibited (HT: 773% versus NT:
944% CVCmax; P0.0004) sites compared with the nor-
motensive group but was restored in the hypertensive group
at the iNOS-inhibited sites (HT: 899% versus NT: 932%;
P0.39). A greater decrease in %CVCmax with NOS inhibi-
tion was present in the normotensive group at the control
(HT: 424% versus NT: 576% CVCmax; P0.039) and
nNOS-inhibited (HT: 415% versus NT: 625% CVCmax;
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Figure 1. Representative skin blood flow tracings
during local heating for a normotensive and
essential hypertensive subject. The characteristic
phases of the local heating response are labeled:
initial peak, nadir, local heating plateau, and post–
NG-nitro-L-arginine methyl ester (L-NAME) plateau.
The difference between the plateau and the post–
L-NAME plateau indicates the vasodilation attrib-
uted to the production of NO.
Table 2. Absolute Maximum CVC at Each Drug Site for
Normotensive and Hypertensive Subjects During the Local
Heating Protocol
Group
Maximum CVC
Control
nNOS
Inhibited
iNOS
Inhibited
NOS
Inhibited
Normotensive 1.790.28 1.700.19 1.860.23 1.810.12
Hypertensive 1.560.15 1.900.28 1.530.25 1.560.34
CVC indicates cutaneous vascular conductance; nNOS, neuronal NO syn-
thase; iNOS, inducible NO synthase; NOS, NO synthase. There were no
differences between groups or with localized microdialysis drug interventions
(2-way repeated-measures ANOVA). Values are presented as meanSEM.
P0.001) sites, but no difference was present at the iNOS-
inhibited site (HT: 608% versus NT: 566% CVCmax;
P0.39). The plateau in %CVCmax during local heating at the
continuous L-NAME site (nonspecific NOS inhibited) was
greater in the normotensive compared with the hypertensive
group (Figure 2D; P0.001). A significant difference in
%CVCmax between groups was observed during local heating
at the iNOS-inhibited site (1400 W) during the initial peak
(HT: 6010% versus NT: 494% CVCmax; P0.04) and
nadir (HT: 488% versus NT: 303% CVCmax; P0.0002).
No differences in %CVCmax were present between groups at
any of the other pharmacological sites for baseline, initial
peak, or nadir during local heating. There were also no
differences in absolute maximal CVC with localized micro-
dialysis treatment or between groups (Table 2) (P0.05).
Figure 3 shows the mean Ach dose-response curves for
both groups in each drug treatment site. Ach-induced vaso-
dilation was attenuated at all of the concentrations of Ach
0.1 mmol/L in the control sites and 1 mmol/L of Ach in
the nNOS-inhibited sites in the hypertensive compared with
the normotensive group (all P0.05; see Figure 3). Ach-
induced vasodilation was restored with iNOS inhibition in the
hypertensive group compared with their control sites. In
addition, there were no longer differences between the hy-
pertensive and the normotensive groups in %CVCmax in the
sites where iNOS was inhibited. Vasodilation was attenuated
at all of the Ach concentrations with nonspecific NOS
inhibition in both groups compared with their respective
control sites, but vasodilation was greater in the hyperten-
sive compared with the normotensive group at all doses
from 1 to 50 mmol/L of Ach (1.0 mmol/L P0.01, 5 and
10 mmol/L P0.001, and 50 mmol/L P0.01) but not
100 mmol/L of Ach.
Figure 4 shows densitometric analysis and representative
Western blots of nNOS, iNOS, eNOS, and pVASP from the
skin biopsy samples for both groups. There were no differ-
ences in eNOS or nNOS expression between the groups.
iNOS expression was increased (P0.006) and pVASP
(P0.046) was decreased in skin samples from the essential
hypertensive group.
Discussion
The major new findings of the present study were that
cutaneous NO-dependent vasodilation to both physiological
and pharmacological stimuli is attenuated in essential hyper-
tensive human skin and acute iNOS inhibition with 1400 W
increased NO-dependent vasodilation likely through eNOS-
mediated mechanisms. In response to endothelium-dependent
agonists, vasodilation was increased in the essential hyper-
tensives when all of the NOS isoforms were inhibited
compared with the normotensive group. In vitro analysis of
skin biopsy tissue showed that iNOS protein expression was
increased but there were no differences in the constitutively
expressed NOS isoforms. Furthermore, pVASP was reduced
in the hypertensive skin samples, suggesting that functional
NOS activity at the level of the vascular smooth muscle is
decreased. Together these findings suggest that reduced
functional NO production from eNOS contributes to cutane-
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Figure 2. Cutaneous vascular conductance (%CVCmax) at the pla-
teau in skin blood flow during local warming and after NO syn-
thase (NOS) inhibition with NG-nitro-L-arginine methyl ester
(L-NAME) in normotensive and essential hypertensive subjects in
the (A) control site, (B) the neuronal NOS (nNOS)-inhibited site, (C)
the inducible NOS (iNOS)-inhibited site, and (D) the nonspecific
NOS-inhibited site. The black bars indicate %CVCmax at the pla-
teau and the gray bar indicates %CVCmax at the post–L-NAME pla-
teau. NO-dependent vasodilation during local heating is the differ-
ence between the bars and is shown (meanSEM). Values
significantly different from the normotensive group: *P0.05;
**P0.001.
ous microvascular dysfunction in essential hypertensive hu-
mans and may be related to an upregulation in iNOS.
The present data identify iNOS upregulation as a possible
target contributing to attenuated NO-dependent vasodilation
in essential hypertensive humans. One putative mechanism
that may be contributing to hypertension-associated micro-
vascular dysfunction is an iNOS-mediated upregulation of
arginase activity. Arginase is the final enzyme of the urea
cycle and competes with eNOS for the common substrate
L-arginine, resulting in reduced NO bioavailability, and par-
tially mediating eNOS uncoupling,14 where eNOS produces
superoxide instead of NO.30 In animal models of essential
hypertension, increased arginase activity contributes to endo-
thelial dysfunction and inward vessel remodeling through the
downstream production of polyamines.31,32 Because the af-
finity of arginase for L-arginine is considerably lower than
eNOS, direct substrate competition is unlikely in healthy
individuals,33,34 because such acute arginase inhibition is
ineffective at increasing NO-dependent vasodilation in young
and middle-aged healthy humans.35 However, recent work
has established an iNOS-dependent upregulation of arginase
activity through S-nitrosylation as a mechanism for limiting
NO production through eNOS. This posttranslational mech-
anism acts to stabilize arginase and alter its substrate affinity,
allowing it to compete with eNOS for L-arginine.13,36 Al-
though we did not measure arginase activity in the present
data because of the limited protein obtained from the skin
biopsy samples, we have shown in other studies that acute
arginase inhibition augments NO-dependent vasodilation in
essential hypertensive human skin.19,37 Further research into
the link among augmented iNOS, arginase, and microvascu-
lar dysfunction is necessary.
In vitro analysis of the skin biopsies showed that the
downstream vascular smooth muscle NO target pVASP was
decreased in samples obtained from the hypertensive group.
This is consistent with the functional in vivo findings of
attenuated NO-dependent vasodilation during local heating
and pharmacological perfusion of the endothelium-dependent
agonist Ach. Because pVASP is a general downstream
vasodilatory molecule, there are limits to the mechanistic
interpretation of these data. However, these data together
suggest that NO synthesized by iNOS is not having a
vasodilatory effect on the vascular smooth muscle. Instead, in
the pro-oxidant environment characteristic of hypertension, it
is more likely that iNOS synthesized NO is rapidly oxidized
and converted to peroxynitrite. This potential mechanism is
supported by the increase in NO-dependent vasodilation
observed when high concentrations of the nonspecific anti-
oxidant ascorbate are acutely administered in hypertensive
humans.19
In the present study we have initially focused on charac-
terizing the involvement of the NOS isoforms in attenuated
vasodilation with essential hypertension. Our current findings
suggest that increased iNOS expression has potential down-
stream interaction through the constitutive NOSs (mainly
eNOS). However, the initial stimulus (or stimuli) that in-
creases iNOS in hypertensive cutaneous microvasculature
remains unclear. Possible candidates include a host of im-
mune modulators, including tumor necrosis factor-, inter-
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Figure 3. Cutaneous vascular conductance (%CVCmax) in normo-
tensive and essential hypertensive subjects during acetylcholine-
induced vasodilation across a series of concentrations in the (A)
control site, (B) the neuronal NO synthase (nNOS)-inhibited site, (C)
the inducible NO synthase (iNOS)-inhibited site, and (D) the non-
specific NOS inhibited site (NG-nitro-L-arginine methyl ester
[L-NAME]). Values are significantly different from the normotensive
group: *P0.05, **P0.01, **P0.001.
leukin 6, cyclooxygenase 2, and elevated angiotensin II.38 As
such, potential pharmacological targets for the treatment of
hypertension-induced microvascular dysfunction include the
angiotensin pathway and novel anti-inflammatory com-
pounds, such as acromalin, which decreases iNOS and
cyclooxygenase 2 expression by altering tumor necrosis
factor- and interleukin 6.39
An additional interesting finding from the present data set
was that vasodilation was increased in the hypertensive group
when all of the NOS isoforms were inhibited in response to
the endothelium-dependent agonist Ach (compared with the
normotensive group). There are many possible explanations
for this finding in addition to decreased functional NO
bioavailability. First, there may be other non–NO-dependent
mechanisms that are upregulated with hypertension acting as
a compensatory mechanism for decreased eNOS activity,
including endothelium -derived hyperpolarization factors and
both vasoconstrictor and vasodilatory products of the arachi-
donic acid pathway. Secondly, increased superoxide dismu-
tase production from uncoupled eNOS and other
hypertension-associated elevations in the activity of enzymes
NAD(P)H oxidase and xanthine oxidase1,2 may lead to a
relative vasoconstriction. Superoxide is capable of inducing
vasoconstriction through the Rho/Rho-kinase pathway in the
vascular smooth muscle and has been identified mechanisti-
cally as one signal inducing vasoconstriction in human
skin.40–42 Furthermore, this mechanism is implicated in
microvascular dysfunction with primary aging.43–45 Thus,
inhibiting the uncoupled eNOS with L-NAME would de-
crease superoxide production and result in increased blood
flow with increasing concentrations of Ach.
In the present study we did not find a significant difference
in absolute maximal cutaneous vascular conductance as we
and others have demonstrated using similar techniques in
unmedicated essential hypertensive humans.19,37 This differ-
ence likely reflects the relatively young age and stage 1
hypertensive status of our population. Moreover, it suggests
that the disease progression begins with a relative endothelial
dysfunction and then moves on toward vascular smooth
muscle hypertrophy and inward vessel remodeling.
We have used the cutaneous circulation to examine a
potential mechanism underlying hypertension-induced micro-
vascular dysfunction in humans. Using both physiologically
relevant and pharmacological stimuli, our results are consis-
tent with findings from other regional circulations46 and
demonstrate a globalized endothelial dysfunction. Although
the cutaneous circulation is being recognized as a useful
model for examining hypertension-induced microvascular
dysfunction, it should be acknowledged that the sympathetic
neural innervation is specialized for thermoregulatory func-
tions and does not significantly contribute to overall blood
pressure control. However, recent findings specific to essen-
tial hypertensive vascular pathology suggest that the changes
occurring in the cutaneous circulation parallel those that
occur in the renal vascular bed,5 which is important in blood
pressure regulation.
Limitations
Men and women demonstrate differences in cardiovascular
risk, and several studies have demonstrated important differ-
ences in endothelial function between men and women. In
this study we included both men and women, but the groups
were not evenly matched for sex, and 2 premenopausal
women were included (1 in each group). It would have been
ideal to match the groups evenly for sex and menopausal
status. However, whereas sex differences have been observed
in the reflex regulation of thermoregulatory skin blood flow
because of differences in sympathetic control, little evidence
exists for potential differences in the regulation of skin blood
flow during local heating or the perfusion of endothelium-
dependent agonists.
We did not measure a total index of direct NOS activity in
the skin samples. Because of the limited number of skin
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Figure 4. NO synthase (NOS) 1, NOS2, NOS3, vasodilatory-stimulated phosphoprotein (VASP), and phosphorylated VASP (pVASP).
Expressions of the 3 NOS enzymes and VASP and pVASP activity were determined by Western blotting. GAPDH was used as loading
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*P0.05 difference from the normotensive group.
samples per subjects and protein recovery per sample, we
were not able to successfully measure total NOS activity. One
reason for this was that there are several endogenous enzyme-
independent sources of NO in the skin that increase with UV
light exposure,47 leading to an unfavorable signal:noise ratio.
Instead, we measured a downstream vascular smooth muscle
indicator of NOS activity, demonstrating that it is decreased in
samples from essential hypertensive humans. Finally, we at-
tempted to probe for phosphorylated eNOS; however, because
of the time lapse between the initial analysis and labile nature of
these proteins, they were not detectable.
Perspectives
Hypertension-associated vascular dysfunction is a complex,
multifaceted condition that occurs simultaneously in multiple
vascular beds. Attenuated NO-dependent dilation in the
cutaneous circulation may precede alterations in conduit
vessels,9,19,37,48–51 making the skin an easily accessible,
generalizable vascular bed for assessing in vivo vascular
function and dysfunction in preclinical and cardiovascular
disease groups.4,10,52,53 The present data indicate a mech-
anistic link between inflammation and attenuated NO-
dependent vasodilation in hypertensive humans. Because
iNOS inhibition restored locally mediated vasodilation in
the hypertensive group, iNOS may be a potential molecular
target in the treatment of essential hypertension-induced
vascular dysfunction.
In summary, cutaneous NO-dependent vasodilation to both
physiological and pharmacological stimuli is attenuated in
essential hypertensive human skin. iNOS expression was
increased in skin samples from essential hypertensive humans
and acute iNOS inhibition restored NO-dependent vasodila-
tion, likely through eNOS mechanisms. In addition, the
downstream functional NO target pVASP was reduced in
hypertensive skin samples. Together these findings suggest
that reduced functional NO production from eNOS contrib-
utes to cutaneous microvascular dysfunction in essential
hypertensive humans and may be related to an upregulation in
iNOS.
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